La artritis reumatoide es una enfermedad autoinmune crónica que causa daño articular progresivo, pérdida funcional y comorbilidad. La artritis reumatoide activa no controlada causa daño articular, discapacidad, disminución de la calidad de vida y enfermedades cardiovasculares y otras comorbilidades. Los fármacos antirreumáticos modificadores de la enfermedad (FARME), los agentes terapéuticos clave, reducen la sinovitis y la inflamación sistémica y mejoran la función, los agentes biológicos se utilizan cuando la artritis no está controlada o cuando surgen efectos tóxicos; sin embargo, las infecciones y los altos costos restringen la prescripción de agentes biológicos. En el Perú, estos medicamentos no se encuentran en el Petitorio Nacional Único de Medicamentos Esenciales, por lo que es necesario evaluaciones económicas o análisis de impacto presupuestal a fin de deter...

Objective: This is a pharmacoeconomic evaluation of two therapy schedules using drugs with different modes of action: Degarelix and triptorelin in the treatment of patients with advanced hormone-dependent prostate cancer. Methods: We reviewed the literature on the standard treatment for these patients, early and late effects of existing therapies, and we also performed a valuation using the Comprehensive Cost Treatment EsSalud (Peruvian Social Security) rates. Results: The Comprehensive Cost Treatment is S/. 10 793 for a patient using Degarelix and S/. 12 251 for a patient using generic triptorelin, so the therapy with the GnRH antagonist generates S/. 1 458 savings per patient. Conclusions: This represents S/. 1,008,017 savings for all patients with advanced hormone-dependent prostate who attend to EsSalud, with the added advantage that there are no extra costs with ...

Objective: This is a pharmacoeconomic evaluation of two therapy schedules using drugs with different modes of action: Degarelix and triptorelin in the treatment of patients with advanced hormone-dependent prostate cancer. Methods: We reviewed the literature on the standard treatment for these patients, early and late effects of existing therapies, and we also performed a valuation using the Comprehensive Cost Treatment EsSalud (Peruvian Social Security) rates. Results: The Comprehensive Cost Treatment is S/. 10 793 for a patient using Degarelix and S/. 12 251 for a patient using generic triptorelin, so the therapy with the GnRH antagonist generates S/. 1 458 savings per patient. Conclusions: This represents S/. 1,008,017 savings for all patients with advanced hormone-dependent prostate who attend to EsSalud, with the added advantage that there are no extra costs with ...